融合活检市场机会、成长驱动因素、产业趋势分析和 2025 年至 2034 年预测

2024 年全球融合活检市场价值为 8.291 亿美元，预计 2025 年至 2034 年将以 9.9% 的年复合成长率(CAGR) 增长。对早期发现、支持性政府政策和报销计划的认知。

融合活检结合了 MRI 和超音波成像，透过针对特定区域进行活检来提高诊断精度。这项先进技术在检测前列腺癌方面发挥着至关重要的作用，前列腺癌在老年男性中非常普遍。传统的活检方法通常缺乏早期诊断所需的准确性，但融合活检透过提供清晰、即时的影像来指导活检过程，从而克服了这一限制。此方法的精确度对于确保准确诊断、减少假阴性和改善前列腺癌的治疗至关重要，特别是对于接受主动监测的患者。

市场分为两大类：设备和配件。包括MRI 超音波融合系统在内的设备细分市场在2024 年以7.031 亿美元的收入引领市场。精确指导活检程序的能力。随着医疗机构越来越注重高品质的诊断工具，对融合活检设备的需求持续成长。

市场的手术部分分为经直肠和经会阴手术。经直肠入路在 2024 年创造了 6.776 亿美元的收入，预计 2025 年至 2034 年间将以 9.6% 的复合年增长率增长。

融合活检主要用于前列腺癌诊断，但也可用于肾臟癌和其他领域。由于检出率的提高以及对早期筛检和准确诊断的日益重视，前列腺癌诊断领域在 2024 年产生了最高的收入。这项需求进一步受到旨在鼓励早期发现的提高认识活动的推动，从而改善生存结果。

医院是融合活检技术的主要最终用户，其先进的基础设施和训练有素的医务人员支持其市场份额。这些设施配备了必要的成像技术来进行精确的融合活检，使其成为这些手术的首选设置。

北美市场是主要的成长动力，对全球市场收入做出了重大贡献。该地区先进的医疗基础设施，加上前列腺癌的高发病率，支持越来越多地采用融合活检技术作为标准诊断工具。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 摄护腺癌盛行率增加
    • 成像技术的进步
    • 提高认识和筛检计划
    • 政府支持政策和报销
  • 产业陷阱与挑战
    • 设备和流程成本高
• 成长潜力分析
• 监管环境
• 报销场景
• 技术景观
• 未来市场趋势
• 差距分析
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 战略仪表板

第 5 章：市场估计与预测：按产品类型，2021 - 2034 年

• 主要趋势
• 装置
• 配件

第 6 章：市场估计与预测：按程序类型，2021 - 2034 年

• 主要趋势
• 经直肠
• 经会阴

第 7 章：市场估计与预测：按应用划分，2021 - 2034 年

• 主要趋势
• 前列腺癌诊断
• 肾臟癌诊断
• 其他应用

第 8 章：市场估计与预测：按最终用途，2021 - 2034 年

• 主要趋势
• 医院
• 诊断影像中心
• 门诊手术中心
• 其他最终用户

第 9 章：市场估计与预测：按地区划分，2021 - 2034 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第 10 章：公司简介

• Canon Medical Systems
• CIVCO Medical Solutions
• Eigen Health
• Esaote SpA
• Exact imaging
• Focal Healthcare
• GE HealthCare
• Koelis
• Koninklijke Philips NV
• MedCom
• Merit Medical Systems
• Siemens Healthineers

The Global Fusion Biopsy Market was valued at USD 829.1 million in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 9.9% from 2025 to 2034. The market's rapid expansion is driven by the increasing prevalence of prostate cancer, growing awareness of early detection, and supportive government policies and reimbursement programs.

Fusion biopsy combines MRI and ultrasound imaging to enhance diagnostic precision by targeting specific areas for biopsy. This advanced technique plays a crucial role in detecting prostate cancer, which is highly prevalent among older men. Conventional biopsy methods often lack the accuracy needed for early diagnosis, but fusion biopsy overcomes this limitation by providing clear, real-time images that guide the biopsy procedure. The method's precision is crucial for ensuring accurate diagnoses, reducing false negatives, and improving the management of prostate cancer, especially for patients undergoing active surveillance.

The market is divided into two main categories: devices and accessories. The devices segment, which includes MRI-ultrasound fusion systems, led the market with a revenue of USD 703.1 million in 2024. These systems are essential for improving diagnostic accuracy in prostate cancer detection, offering clinicians enhanced visibility and the ability to precisely guide biopsy procedures. As healthcare facilities increasingly focus on high-quality diagnostic tools, the demand for fusion biopsy devices continues to rise.

The procedure segment of the market is categorized into transrectal and transperineal approaches. The transrectal approach generated USD 677.6 million in 2024 and is expected to grow at a 9.6% CAGR between 2025 and 2034. This method is widely preferred for its ability to target specific lesions within the prostate with accuracy, thanks to its established procedural framework and the familiarity of healthcare providers with its use.

Fusion biopsy is primarily used for prostate cancer diagnosis, although it also has applications in kidney cancer and other areas. The prostate cancer diagnosis segment generated the highest revenue in 2024, benefiting from improved detection rates and the growing emphasis on early screening and accurate diagnosis. This demand is further driven by heightened awareness campaigns aimed at encouraging early detection, which improves survival outcomes.

Hospitals are the dominant end users of fusion biopsy technology, with a market share supported by their advanced infrastructure and highly trained medical staff. These facilities are equipped with the necessary imaging technologies to perform accurate fusion biopsies, making them the preferred setting for these procedures.

The North America market is a key growth driver, contributing significantly to the global market revenue. The region's advanced healthcare infrastructure, coupled with high prostate cancer incidence rates, supports the growing adoption of fusion biopsy techniques as a standard diagnostic tool.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of prostate cancer
    • 3.2.1.2 Advancements in imaging technology
    • 3.2.1.3 Growing awareness and screening programs
    • 3.2.1.4 Supportive government policies and reimbursement
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of equipment and procedures
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Reimbursement scenario
• 3.6 Technology landscape
• 3.7 Future market trends
• 3.8 Gap analysis
• 3.9 Porter's analysis
• 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Devices
• 5.3 Accessories

Chapter 6 Market Estimates and Forecast, By Procedure Type, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Transrectal
• 6.3 Transperineal

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Prostate cancer diagnosis
• 7.3 Kidney cancer diagnosis
• 7.4 Other applications

Chapter 8 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Hospitals
• 8.3 Diagnostic imaging centers
• 8.4 Ambulatory surgical centers
• 8.5 Other end users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 Canon Medical Systems
• 10.2 CIVCO Medical Solutions
• 10.3 Eigen Health
• 10.4 Esaote SpA
• 10.5 Exact imaging
• 10.6 Focal Healthcare
• 10.7 GE HealthCare
• 10.8 Koelis
• 10.9 Koninklijke Philips N.V.
• 10.10 MedCom
• 10.11 Merit Medical Systems
• 10.12 Siemens Healthineers